Physician profile
Alan H Bryce
NPI 1548246655
$156,888.21
in general payments reported to CMS, 2019-2025
34 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $14K · 2021: $12K · 2022: $18K · 2023: $35K · 2024: $26K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $57K · Food and Beverage: $12K · Travel and Lodging: $3,166 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,812 · Honoraria: $1,800 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $56,708.50 |
| Food and Beverage | $12,148.02 |
| Travel and Lodging | $3,166.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,812.00 |
| Honoraria | $1,800.00 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32,201.59 | 2019-2024 | |
| Pfizer INC. | $28,519.43 | 2019-2025 | |
| Clovis Oncology, INC. | $16,449.24 | 2019-2022 | |
| Astellas Pharma US INC | $11,712.70 | 2019-2024 | Xtandi |
| Astellas Pharma Global Development | $10,000.00 | 2023-2025 | Xtandi |
| Pharmaand Gmbh | $9,541.71 | 2024 | Rubraca |
| Advanced Accelerator Applications | $8,534.32 | 2019-2022 | |
| Genzyme Corporation | $8,365.76 | 2023 | |
| Tolmar, INC. | $7,300.00 | 2024-2025 | |
| Janssen Biotech, INC. | $5,618.85 | 2019-2025 | Erleada |
| Lantheus Medical Imaging, INC. | $4,491.09 | 2024 | |
| Janssen Scientific Affairs, LLC | $4,421.34 | 2019-2025 | Erleada, Akeega, Balversa |
| Eli Lilly and Company | $3,200.00 | 2023 | |
| Merck Sharp & Dohme LLC | $2,250.00 | 2020 | |
| Foundation Medicine, INC. | $1,500.00 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,370.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $467.24 | 2021-2025 | |
| Progenics Pharmaceuticals, INC. | $416.72 | 2023-2025 | Pylarify |
| Bayer Healthcare LLC | $149.78 | 2025 | |
| Blue Earth Diagnostics | $75.88 | 2023 | |
| Abbvie INC. | $66.21 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $55.90 | 2025 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $32.78 | 2025 | Libtayo |
| Genentech USA, INC. | $31.76 | 2024 | Rozlytrek, Lunsumio, Alecensa |
| Daiichi Sankyo INC. | $27.98 | 2025 | Vanflyta |
| Seagen INC. | $27.92 | 2023 | |
| Celgene Corporation | $24.39 | 2025 | Reblozyl |
| Servier Pharmaceuticals LLC | $23.70 | 2025 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Bryce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.